Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.99
- Piotroski Score 3.00
- Grade Buy
- Symbol (STRO)
- Company Sutro Biopharma, Inc.
- Price $3.63
- Changes Percentage (-1.63%)
- Change -$0.06
- Day Low $3.60
- Day High $3.74
- Year High $6.13
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $15.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.88
- Trailing P/E Ratio -1.97
- Forward P/E Ratio -1.97
- P/E Growth -1.97
- Net Income $-106,793,000
Income Statement
Quarterly
Annual
Latest News of STRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Altice USA Inc (ATUS) Q3 2024 Earnings Call Highlights: Strategic Cost Reductions and Strong ...
CEO Dennis Mathew and CFO Marc Sirota discuss leveraging mobile, AI, and digital initiatives to optimize efficiency, reduce costs, and drive revenue growth in the company. They aim to become a digital...
By Yahoo! Finance | 7 hours ago -
Intapp Inc (INTA) Q1 2025 Earnings Call Highlights: Strong SaaS Growth and Strategic ...
CEO John Hall discusses the impact of alliances, particularly with Microsoft, on revenue growth. The partnership involves increased co-marketing, co-selling, and availability on the Azure marketplace....
By Yahoo! Finance | 7 hours ago -
The Baldwin Insurance Group Inc (BWIN) Q3 2024 Earnings Call Highlights: Strong Organic Growth ...
CEO Trevor Baldwin expressed confidence in accelerating Q4 IAS growth despite construction delays, citing new business visibility and easier comparisons. He identified potential macroeconomic slowdown...
By Yahoo! Finance | 7 hours ago
